[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 2.48% 82.60 81.40 82.60 82.60 80.40 80.40 163,853 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 33.7 383

Ekf Diagnostics Share Discussion Threads

Showing 3801 to 3822 of 3950 messages
Chat Pages: 158  157  156  155  154  153  152  151  150  149  148  147  Older
DateSubjectAuthorDiscuss
14/9/2021
16:30
Isn't it annoying when an absolute tool who has been floating on a lifeless stock for a year doesn't appreciate the wake up call? Lol.
tongosti
14/9/2021
16:04
isn't it annoying that when this guy with a Tong gets into buying a share he has to post every nonsensical thing you can think about but when we have reputable posters posting valuable insights over a long period he mocks them? Beware new holders
mg1982
14/9/2021
15:56
Tremendous volume.
tongosti
14/9/2021
14:14
Happy to continue holding this outstanding company for the long-term (assuming nothing dramatic happens). The chart over the last 18 months says all that's needed about how EKF's prospects have transformed - partly fortuitously it must be said - and how the company's strategy is paying off in spades. And shareholders have benefited twice over taking into account the various spin-offs, with more likely over time.
rivaldo
14/9/2021
14:05
86.80 offered. Yes - it is a vĂ¡lid breakout to all time highs. Now let's see how this baby will hold and whether we get a decent follow up tomorrow (very important).
tongosti
14/9/2021
12:40
Https://www.insidermedia.com/news/wales/ekf-to-outstrip-already-upgraded-expectations Https://www.business-live.co.uk/enterprise/ekf-diagnostics-again-upgrades-trading-21563514
mirandaj
14/9/2021
12:39
Putting my money where my mouth is. Just upgraded to full exposure (keeping it on an even tighter leash than before to keep %risk at same level as when I was half way in). Since this is a game of odds - they do imply this is very probably THE moment this baby meaningfully breaks out (following a very very long year for a good few on here:). If not - protecting one's backside is the name of the game. As the wise man said ... avoiding defeat lies in our own hands, the chance of victory is provided by Providence itself. Come on EKF!
tongosti
14/9/2021
12:25
Knocking on the heaven's door?Wan - this is where you should be at your loudest. When price action is VERY close to validate your thesis pal. Only Mr Market's vote makes or loses one a few copper coins. Tic toc fellas - will it or won't it?
tongosti
14/9/2021
11:32
Good volumes substantiating today's move. As the wise man said, volumes are the equivalent of votes at different price levels.
tongosti
14/9/2021
10:55
Like I said earlier, it's now or never time. Have to say the price is indeed acting as it should after a very long time. No guarantees of course but it looks like we could really break out v strongly today. It hasn't happened in a long while but ekf is the only stock that has all my full attention today.
tongosti
14/9/2021
09:26
To be clear re my typo comment, it's not the amount per se, which is down to the changes in working capital and the increase in inventory (I am not an accountant), which is ultimately a result of the increase in order volume and also to ensure security of component supply (which is obviously paramount). In other words, presumably that will show up in the second half, hence the boards confidence in the outcome in terms of outperformance, not to mention that Singer may once again prove conservative (which is not a bad thing!)
wan
14/9/2021
09:23
Singer have upgraded and has published a new research note on EKF - EKF has delivered another strong set of results, with the step change in the scale of the business firmly consolidated. H1 revenues increased 46.5% driven by an ongoing recovery in the core business and strong demand from a number of public and private sector customers for sample collection devices. The outlook remains positive and progress is being made against the new strategy set out earlier in the year. We upgrade our FY21 revenue forecasts by 7% and EBITDA by 13% noting this still implies an H1 weighting to results, which may again prove to be overly conservative. With growth opportunities on a number of fronts, we continue to see a strong investment case for EKF. hTTps://www.research-tree.com/companies/uk/ekf-diagnostics-holdings-plc/research/singer-capital-markets/strong-interims-further-upgrades/d8bbfdfd-9587-451c-96ea-6705cecf1940
wan
14/9/2021
08:46
Now this is the chance of the stock price to react. It's now or never time. Still in with my half risk position bu happy to upgrade to a full one IF this acts differently this time.
tongosti
14/9/2021
08:20
yes wan - typo-I thought that looked a bit odd
9degrees
14/9/2021
07:58
Another upgrade, excellent Results and outlook! Pleased to see that we have a new heading "infectious disease", and very pleased to see that revenues are set to grow further under this heading and will also be driven from non-COVID-19 indications and 'importantly' from a broader customer base. It will thus be very interesting learn what non-COVID-19 tests are in demand and ultimately contracted for (especially given the up and coming winter cold/flu season). A very encouraging and heathy position! (There appears to be a typo regarding cash generated in H1, which is referred to as H1 2020)
wan
14/9/2021
07:42
Away at present, so unable to catch up with management this time around. But, like others delighted by today's news.
hastings
14/9/2021
07:28
Lovely to see this today.... "The Board is very confident that trading for the year ending 31 December 2021 will be comfortably ahead of already upgraded management expectations" Interesting to see that EKF are opening new facilities in relation to COVID testing kits "with the expectation that sales of these products will continue for the foreseeable future", and that "we are now discussing the supply of products for non-COVID-19 indications" resulting from the success of the COVID test kits. Plus encouraging to hear that the core business "is capable of generating significant double-digit growth in adjusted EBITDA over the next three to four years".
rivaldo
14/9/2021
07:26
Half-year Report: Further upgrade to current year trading EKF Diagnostics Holdings announces its unaudited interim results for the six months ended 30 June 2021, as well as a further upgrade to current year trading. The strong trading from the beginning of the year continued into the second quarter of 2021. This continues to reflect improving trading in the core business and ongoing strong demand for EKF's contract manufacturing services for COVID-19 sample collection devices and associated kits. The Board is now very confident that trading for the full year will be comfortably ahead of already materially upgraded management expectations. Financial Highlights -- Revenue up 46.5% to £38.56m (H1 2020: £26.33m) -- Adjusted EBITDA* up 42.9% to £12.76m (H1 2020: £8.93m) -- Net profit after tax up 122% to £9.19m (H1 2020: £4.14m) -- Net cash generated from operations of £1.13m (H1 2020: £6.94m) -- Net cash of £20.38m (30 June 2020: £16.28m) (31 December 2020: £21.41m) -- Dividend of 1.1p per share to be paid on 1 December 2021 (record date: 5 November 2021) Operational Highlights -- Core business revenues up £1.21m (6%) in first six months of 2021 -- Life Sciences revenues including contract manufacturing for PrimeStore MTM & PBS up 142% to £18.50m -- Signed multi-million dollar global supply contract for phosphate-buffered saline (PBS) with global private sector partner, whilst broadening customer base and reducing reliance on this single customer -- Opened new PrimeStore MTM and PBS manufacturing facilities in Cardiff and Boerne to meet wider customer demand in UK and USA -- Trellus Health admitted to AIM on 28 May 2021 Christopher Mills, Non-Executive Chairman of EKF, commented:"The Board is very confident that trading for the year ending 31 December 2021 will be comfortably ahead of already upgraded management expectations. The Group remains confident that its growth strategy, as outlined to shareholders at the Annual General Meeting in May, and set out above, will create a business which, aside from any COVID-19 related revenues, is capable of generating significant double-digit growth in adjusted EBITDA over the next three to four years."
masurenguy
12/9/2021
07:15
Quality will ultimately count - Health and Social Care Secretary, Sajid Javid said: It is completely unacceptable for any private testing company to take advantage of holidaymakers and we are taking action to clamp down on cowboy behaviour. I requested a review from the Competition and Markets Authority to address exploitative behaviour in the private testing market and ensure the government is doing everything it can to crack down on excessive pricing and inaccurate claims. Through our regular reviews and spot-checks, we have identified even more providers that were messing around with costs and have now removed 91 providers from Gov.uk and corrected inaccurate prices of 135 private providers who will be removed from the list if they advertise misleading prices again. From 21 September, in order to ensure travel test providers are performing to a high legalised standard, there will be tough new penalties for companies that fail to follow the law, including fixed fines of up to £10,000. I am reviewing the recommendations from the Competition and Markets Authority and will outline further changes shortly to ensure consumers are given the best tests at the very best prices. Published 11 September 2021 hTTps://www.gov.uk/government/speeches/response-to-cma-recommendations-regarding-pcr-travel-test-market
wan
12/9/2021
06:53
According to a number of reports, the government is understood to be considering dropping the requirement for double-vaccinated passengers to take a laboratory-based PCR test when arriving in the UK from most countries from October and would bring the UK into line with many European countries. Apparently later flow tests may still be required (and presumably a PCR test if negative). And in any regard, and not before time, further intervention is imminent - CMA publishes recommendations to improve PCR testing market The CMA has published advice to the UK Government on ways to make the PCR testing market work better for consumers. From: Competition and Markets Authority Published 10 September 2021 The Competition and Markets Authority (CMA) has found there are features of the PCR testing market which mean competition alone will not deliver the right outcomes for consumers. There is a risk of a ‘race to the bottom’, in which providers compete on grounds other than high clinical quality and travellers end up losing out. Full release worth reading - hTTps://www.gov.uk/government/news/cma-publishes-recommendations-to-improve-pcr-testing-market
wan
11/9/2021
06:54
Adam Reynolds will be pleased..... https://www.marketscreener.com/quote/stock/YOURGENE-HEALTH-PLC-16860916/news/Yourgene-Health-Wins-GBP34-1-Million-Covid-19-Testing-Governmental-Contract-36391831/
mirandaj
11/9/2021
06:49
More information/substance regarding the above post - Biden Administration Details Expanded Testing as Part of Broader COVID-19 Action Plan Sep 10, 2021 NEW YORK – President Biden on Thursday announced a COVID-19 Action Plan that includes initiatives to increase the amount of testing available across the country. The testing and masking portion of the action plan — which also discusses vaccination mandates, economic recovery, and improving COVID-19 patient care — is largely focused on rapid point-of-care and at-home testing for the SARS-CoV-2 virus. Biden said he will use the Defense Production Act to further accelerate production of rapid tests. The federal government will procure 280 million tests from multiple manufacturers to "ensure a broad, sustained industrial capacity for COVID-19 test manufacturing," according to the plan. The tests will be available for long-term care facilities, community testing sites, shelters for unhoused people, prisons and jails, and other vulnerable populations and congregate settings. The increase in manufacturing will also provide for adequate stockpiles of tests and the ability to surge additional manufacturing in the future if necessary, the White House said. In addition, retailers including Walmart, Amazon, and Kroger will sell rapid tests at-cost for the next three months, allowing people to buy the tests for up to 35 percent less than current pricing, the White House said. Medicaid is also required to cover at-home tests for free for beneficiaries. The plan noted that states should make sure that "any tools they use to manage at-home testing do not establish arbitrary barriers for people seeking care." The organizations also recommended leveraging the Strategic National Stockpile to bolster test capacity; ensuring the US Centers for Disease Control contracts directly with labs to retain necessary supplies to surge capacity when needed; providing consistent information to states about testing; allowing states flexibility to modify testing plans; extending the public health emergency; and making CDC's studies on serology and antibody testing public to understand the immune response to COVID-19 vaccines. Full story - hTTps://www.360dx.com/policy-legislation/biden-administration-details-expanded-testing-part-broader-covid-19-action-plan#.YTw_kp1KiF4 Readers will also note the reference to studies on serology and antibody testing.
wan
Chat Pages: 158  157  156  155  154  153  152  151  150  149  148  147  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211028 02:47:27